Edition:
United States

Healthcare

JNJ.N
PFE.N
UNH.N

BRIEF-Amgen's Phase 3 A.R.R.O.W. study of once-weekly KYPROLIS regimen meets primary endpoint

* Phase 3 A.R.R.O.W. study of once-weekly KYPROLIS(carfilzomib) regimen meets primary endpoint of progression-free survival in relapsed and refractory multiple myeloma patients

Stock Quote, 4:05pm EDT

Deals of the day- Mergers and acquisitions

Oct 23 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Monday:

UPDATE 1-FDA warns Meridian of violations for lead-testing devices

Oct 23 The U.S. Food and Drug Administration said on Monday it issued a warning letter to Meridian Bioscience Inc's unit for several federal law violations after inspecting its facility that makes lead-testing devices.

FDA warns Meridian of violations for lead-testing devices

Oct 23 The U.S. Food and Drug Administration said on Monday it issued a warning letter to Meridian Bioscience Inc's unit for several federal law violations after inspecting its facility that makes lead-testing devices.

BRIEF-GE Transportation announces agreement with Rumo​

* Through agreement, co will implement trip optimizer on Rumo's locomotive fleet that runs on North and Sao Paulo lines

Healthcare
Johnson & Johnson $143.62 +0.86%
Pfizer Inc $36.40 -0.05%
UnitedHealth Group Inc $207.01 -0.23%

Markets

  • U.S.
  • Europe
  • Asia
  • Sectors

Sector Summary

Upcoming Events

No related earnings announcements are currently scheduled within the next 7 days.